Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
Statement from the Multiple Myeloma Research Foundation Regarding the Decision by the U.S. Food and Drug Administration (FDA) to Approve Celgene’s REVLIMID® (Lenalidomide) in Newly Diagnosed Multiple Myeloma Patients
Statement from the Multiple Myeloma Research Foundation Regarding the Decision by the U.S. Food and Drug Administration (FDA) to Approve Celgene’s REVLIMID® (Lenalidomide) in Newly Diagnosed Multiple Myeloma Patients
The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the U.S. Food and Drug Administration’s (FDA) approval of Celgene’s REVLIMID® (Lenalidomide) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant.
Norwalk, Conn., February 18, 2015 – The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the U.S. Food and Drug Administration’s (FDA) approval of Celgene’s REVLIMID® (Lenalidomide) in combination with dexamethasone for the treatment of multiple myeloma in all patients.
“Multiple myeloma treatment options have increased significantly over the last decade, resulting in improved survival rates and longer remissions for patients. However, there is still no cure, and due to the complexity of the disease, there remains a critical need to offer a range of therapy options.”
“We are pleased that the FDA has recognized the significant need for additional initial therapy options and granted approval of REVLIMID in combination with dexamethasone for all myeloma patients,” said Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation. “The MMRF is committed to the relentless pursuit of new therapies to treat, and one day cure, this devastating disease. The addition of REVLIMID in combination with dexamethasone brings the multiple myeloma community one step further toward this goal.”
About Multiple Myeloma (MM)
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 26,850 adults (14,000 men and 12,760 women) in the United States will be diagnosed with MM in 2015 and an estimated 11,240 people are predicted to die from the disease. The five-year survival rate for MM is approximately 45%, versus 28% in 1998.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming.
